Brain stem glioma treatment focuses on controlling symptoms, slowing tumor growth, and preserving quality of life through a combination of surgery, radiation, and emerging therapies tailored to each patient’s unique situation.

Understanding Your Treatment Journey

When someone receives a diagnosis of brain stem glioma, the first questions that usually arise concern what can be done and what the path forward looks like. The brainstem is a small but incredibly important part of the brain, controlling essential functions like breathing, heart rate, swallowing, and balance. Because of this critical location, treating tumors in this area requires careful planning and a personalized approach that takes into account the tumor’s exact position, its growth pattern, and the patient’s overall health.

Treatment for brain stem glioma varies significantly depending on several factors. The grade of the tumor—which describes how aggressive the cells appear under a microscope—plays a major role in determining which therapies will be used. Grade I tumors tend to grow slowly and may be easier to manage, while grade IV tumors are highly aggressive and require more intensive treatment. The location within the brainstem also matters greatly: tumors in the midbrain or medulla often behave differently than those in the pons, the middle section of the brainstem.

Medical teams use established treatment guidelines developed by medical societies and cancer centers worldwide, but they also recognize that research is constantly evolving. Many hospitals now offer access to clinical trials testing new drugs and treatment approaches that may provide additional options beyond standard care. These trials are an important part of advancing our understanding of how to treat these complex tumors more effectively.

Standard Treatment Approaches

For patients with focal brainstem gliomas—tumors that stay confined to one area and grow slowly—surgery is often the first step. When a neurosurgeon can safely remove most or all of the visible tumor without damaging surrounding brain tissue, surgery alone can sometimes be curative, particularly for grade I tumors. This means the tumor may not return after complete removal. However, the brainstem’s delicate anatomy means that surgery is not always possible or advisable, as operating in this region carries risks of affecting vital functions.

When surgery cannot safely remove the entire tumor, or when the tumor is more aggressive, radiation therapy becomes a cornerstone of treatment. Radiation uses high-energy rays directed precisely at the tumor to damage cancer cells and stop their growth. The standard approach involves delivering doses between 54 and 60 Gray units over several weeks. This gradual delivery allows healthy brain tissue time to recover between treatments while maximizing the effect on tumor cells.

Radiation therapy can improve or stabilize symptoms in many patients, particularly those with tumors that have an exophytic component—meaning part of the tumor grows outward from the brainstem surface. Patients with these characteristics tend to respond better to radiation than those with tumors that diffusely infiltrate throughout the brainstem tissue.

Chemotherapy involves using medications to kill cancer cells or slow their growth. For brainstem gliomas, particularly those classified as grade III or IV, doctors may prescribe chemotherapy drugs either during or after radiation therapy. The most commonly used medication is temozolomide, which comes as a pill taken once daily. Patients typically take this medication for at least six weeks, often alongside radiation treatment.

Temozolomide is generally well-tolerated compared to older chemotherapy drugs, though it can cause side effects including nausea, fatigue, and temporary changes in blood cell counts. Other chemotherapy options include combinations of carboplatin and vincristine, particularly in children. The choice of chemotherapy depends on the tumor’s characteristics, the patient’s age, and how well they can tolerate treatment.

Some patients may also receive corticosteroids, such as dexamethasone (Decadron), to reduce swelling in the brain caused by the tumor or its treatment. While steroids can provide significant relief from symptoms like headaches and improve neurological function, they also come with side effects including weight gain, increased blood sugar, mood changes, and increased risk of infection. Doctors carefully balance the benefits against these risks when prescribing steroids.

The duration of treatment varies widely. Radiation therapy typically continues for five to six weeks, with treatments five days per week. Chemotherapy may continue for six months to a year or longer, depending on how the tumor responds and how well the patient tolerates the medication. Throughout treatment, regular imaging studies—usually MRI scans—help doctors monitor whether the tumor is shrinking, staying stable, or growing.

Treatment in Clinical Trials

Because standard treatments for brainstem glioma, particularly aggressive types like DIPG, have shown limited success in achieving long-term control, researchers worldwide are actively investigating new approaches through clinical trials. These studies test innovative therapies that may offer hope beyond what current standard treatments can provide.

One promising area of research involves targeted therapy drugs that focus on specific molecular changes found in tumor cells. Scientists have discovered that many brainstem gliomas, especially DIPG tumors, carry a particular genetic mutation called H3 K27M. This mutation changes how genes are regulated in tumor cells and contributes to aggressive growth. Recognizing this, researchers have developed drugs specifically designed to target this pathway.

In August 2025, the U.S. Food and Drug Administration approved dordaviprone (marketed as Modeyso) for treating diffuse midline glioma with the H3 K27M mutation in adults and children aged one year and older who have progressive disease after previous therapy. This approval represents a significant milestone, as it’s the first treatment specifically approved for this type of tumor. The drug works by interfering with how tumor cells regulate their growth and division.

Clinical trials for dordaviprone involved patients who had tried other treatments without success. The studies, which combined data from 50 patients with recurrent H3 K27M-mutant diffuse midline glioma, showed that some patients experienced slowing of tumor growth or stabilization of their symptoms. This kind of benefit, even if temporary, can meaningfully improve quality of life for patients facing limited options.

Anti-angiogenesis drugs represent another approach being tested in clinical trials. These medications work by blocking the formation of new blood vessels that tumors need to grow. Bevacizumab is one such drug that has shown effectiveness in other types of brain tumors. In brainstem gliomas, results have been mixed—some patients experience short-term benefits, but the tumors often eventually find ways to continue growing. Researchers are working to understand why responses vary and how to improve outcomes.

Some clinical trials explore combinations of drugs targeting different aspects of tumor biology. For example, combining traditional chemotherapy with drugs that block specific enzymes or proteins that tumors use to grow might prove more effective than either approach alone. Phase I trials test whether these combinations are safe, Phase II trials examine whether they show signs of working, and Phase III trials compare them directly to standard treatment to determine if they should become the new standard of care.

Immunotherapy approaches are also under investigation. One experimental technique involves dendritic cell immunotherapy, where doctors collect a patient’s tumor cells and white blood cells, then process them in a laboratory to create a personalized treatment that trains the immune system to attack the tumor. While this approach remains experimental, early research suggests it may help some patients’ immune systems better recognize and fight brain tumor cells.

Clinical trials are conducted at specialized medical centers in the United States, Europe, and other regions worldwide. Eligibility for trials depends on many factors including the patient’s age, the specific type and location of tumor, previous treatments received, and overall health status. Doctors encourage patients and families to discuss clinical trial options, as participating not only provides access to potentially beneficial new treatments but also contributes to advancing medical knowledge that may help future patients.

Another area of active research involves improving radiation therapy techniques. Proton therapy, which uses protons instead of traditional X-rays, may allow doctors to deliver radiation more precisely to the tumor while sparing surrounding healthy tissue. Studies are ongoing to determine whether this approach improves outcomes compared to standard radiation.

Gene therapy research is exploring ways to modify tumor cells or introduce new genetic material that makes them more vulnerable to treatment. While these approaches remain largely experimental, early laboratory work and initial human trials show promise. Scientists are also investigating whether certain drugs can cross the blood-brain barrier—a protective membrane that often prevents medications from reaching brain tumors—more effectively than current treatments.

Most common treatment methods

• Surgery
  • Complete or partial removal of focal brainstem gliomas when safely accessible
  • Often curative for grade I tumors when complete resection is achieved
  • Biopsy procedures to obtain tissue for diagnosis and molecular analysis
  • Not typically performed for diffuse intrinsic pontine gliomas due to infiltrative growth pattern
• Radiation therapy
  • Standard doses of 54 to 60 Gray units delivered over several weeks
  • Primary treatment for tumors that cannot be surgically removed
  • Can improve or stabilize symptoms in many patients
  • Particularly effective as additional treatment after surgery for focal tumors
  • Better outcomes reported for tumors with exophytic components
• Chemotherapy
  • Temozolomide taken orally once daily, typically for at least six weeks
  • Often combined with radiation therapy for grade III and IV tumors
  • Carboplatin and vincristine combinations used in some cases
  • May be used at relapse to provide additional benefit
  • Generally better tolerated than older chemotherapy drugs
• Targeted therapy
  • Dordaviprone approved for H3 K27M-mutant diffuse midline gliomas after prior therapy
  • Drugs targeting specific molecular pathways altered in tumor cells
  • Requires molecular testing of tumor tissue to identify appropriate targets
  • Growing area of research with multiple drugs in clinical trials
• Anti-angiogenesis therapy
  • Bevacizumab tested in clinical trials with variable results
  • Works by blocking new blood vessel formation that supports tumor growth
  • May provide short-term benefits in selected patients
• Supportive medications
  • Corticosteroids like dexamethasone to reduce brain swelling
  • Medications to control seizures if they occur
  • Drugs to manage treatment side effects such as nausea